Codexis (CDXS) Competitors $2.69 +0.01 (+0.37%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$2.67 -0.02 (-0.89%) As of 08/1/2025 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CDXS vs. GERN, ZBIO, MYGN, LXRX, EBS, RIGL, VSTM, XOMA, VNDA, and CBIOShould you be buying Codexis stock or one of its competitors? The main competitors of Codexis include Geron (GERN), Zenas BioPharma (ZBIO), Myriad Genetics (MYGN), Lexicon Pharmaceuticals (LXRX), Emergent Biosolutions (EBS), Rigel Pharmaceuticals (RIGL), Verastem (VSTM), XOMA Royalty (XOMA), Vanda Pharmaceuticals (VNDA), and Crescent Biopharma (CBIO). These companies are all part of the "biotechnology" industry. Codexis vs. Its Competitors Geron Zenas BioPharma Myriad Genetics Lexicon Pharmaceuticals Emergent Biosolutions Rigel Pharmaceuticals Verastem XOMA Royalty Vanda Pharmaceuticals Crescent Biopharma Codexis (NASDAQ:CDXS) and Geron (NASDAQ:GERN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, analyst recommendations, dividends, valuation, risk, institutional ownership and earnings. Do analysts recommend CDXS or GERN? Codexis currently has a consensus price target of $11.00, suggesting a potential upside of 308.92%. Geron has a consensus price target of $4.61, suggesting a potential upside of 294.11%. Given Codexis' higher probable upside, equities analysts plainly believe Codexis is more favorable than Geron.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Codexis 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Geron 1 Sell rating(s) 3 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.60 Which has higher valuation & earnings, CDXS or GERN? Codexis has higher earnings, but lower revenue than Geron. Geron is trading at a lower price-to-earnings ratio than Codexis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCodexis$59.35M3.76-$65.28M-$0.99-2.72Geron$116.29M6.41-$174.57M-$0.21-5.57 Does the media refer more to CDXS or GERN? In the previous week, Geron had 3 more articles in the media than Codexis. MarketBeat recorded 5 mentions for Geron and 2 mentions for Codexis. Codexis' average media sentiment score of 1.12 beat Geron's score of -0.21 indicating that Codexis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Codexis 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Geron 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Is CDXS or GERN more profitable? Geron has a net margin of -119.54% compared to Codexis' net margin of -149.47%. Geron's return on equity of -47.86% beat Codexis' return on equity.Company Net Margins Return on Equity Return on Assets Codexis-149.47% -118.47% -53.37% Geron -119.54%-47.86%-26.78% Which has more risk & volatility, CDXS or GERN? Codexis has a beta of 2.54, meaning that its share price is 154% more volatile than the S&P 500. Comparatively, Geron has a beta of 0.73, meaning that its share price is 27% less volatile than the S&P 500. Do insiders and institutionals have more ownership in CDXS or GERN? 78.5% of Codexis shares are held by institutional investors. Comparatively, 73.7% of Geron shares are held by institutional investors. 2.1% of Codexis shares are held by company insiders. Comparatively, 7.4% of Geron shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. SummaryGeron beats Codexis on 11 of the 17 factors compared between the two stocks. Get Codexis News Delivered to You Automatically Sign up to receive the latest news and ratings for CDXS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CDXS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CDXS vs. The Competition Export to ExcelMetricCodexisMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$222.02M$3.00B$5.48B$9.51BDividend YieldN/A2.43%4.73%4.08%P/E Ratio-2.7217.6228.6723.80Price / Sales3.76179.18373.9066.65Price / CashN/A41.9535.4557.96Price / Book3.288.508.275.55Net Income-$65.28M-$55.06M$3.24B$259.03M7 Day Performance-13.50%-3.98%-3.69%-4.59%1 Month Performance-4.27%9.59%4.33%4.46%1 Year Performance-18.48%6.72%25.95%18.03% Codexis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CDXSCodexis3.6994 of 5 stars$2.69+0.4%$11.00+308.9%-22.7%$222.02M$59.35M-2.72250Positive NewsGap DownGERNGeron3.0191 of 5 stars$1.15-8.7%$4.61+301.0%-75.5%$802.52M$76.99M-5.48229Upcoming EarningsHigh Trading VolumeZBIOZenas BioPharma1.6563 of 5 stars$16.45+5.0%$36.67+122.9%N/A$655.12M$5M-4.63N/APositive NewsMYGNMyriad Genetics4.1458 of 5 stars$4.38-1.6%$14.38+228.4%-85.8%$410.19M$837.60M-3.912,700News CoverageUpcoming EarningsGap DownLXRXLexicon Pharmaceuticals2.3945 of 5 stars$1.09-0.9%$3.67+236.4%-47.0%$397.64M$31.08M-2.14140News CoverageUpcoming EarningsEBSEmergent Biosolutions4.5457 of 5 stars$6.77-5.6%$14.33+111.7%-46.6%$389.17M$1.04B-2.502,420Upcoming EarningsGap DownRIGLRigel Pharmaceuticals3.1918 of 5 stars$19.99-0.9%$36.40+82.1%+118.4%$360.48M$203.08M9.66160Positive NewsUpcoming EarningsVSTMVerastem2.4638 of 5 stars$6.02-2.0%$13.38+122.2%+150.2%$337.39M$10K-1.8850News CoverageUpcoming EarningsShort Interest ↑Gap DownXOMAXOMA Royalty3.9209 of 5 stars$26.23+1.5%$69.50+165.0%-3.9%$309.11M$28.49M-22.8110VNDAVanda Pharmaceuticals4.2435 of 5 stars$4.70-0.8%$16.50+251.1%-25.7%$279.35M$198.77M-6.27290Trending NewsEarnings ReportAnalyst DowngradeShort Interest ↑CBIOCrescent Biopharma2.8139 of 5 stars$13.25-0.3%$25.67+93.7%N/A$259.82MN/A-0.2950News CoverageEarnings ReportAnalyst DowngradeGap Down Related Companies and Tools Related Companies GERN Alternatives ZBIO Alternatives MYGN Alternatives LXRX Alternatives EBS Alternatives RIGL Alternatives VSTM Alternatives XOMA Alternatives VNDA Alternatives CBIO Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CDXS) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Codexis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Codexis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
